The future in brief

The global ADHD therapeutics market holds a significant promise for growth, with 2.2% of children and adolescents and 2.8% of adults worldwide diagnosed with ADHD. The Covid-19 pandemic has accelerated the growth rate of the market. Behavioral treatments, which are characterized by low impact on the human CNS and easy accessibility, have become the preferred option for many parents, particularly compared to traditional medications.

According to projections, the digital therapeutics (DTX) market for behavioral treatment is expected to reach $56 billion by 2027. In 2021, North America held the largest share of the global ADHD therapeutics market at 36%. Meanwhile, the Asia Pacific market is expected to experience a compound annual growth rate (CAGR) of 12.3% from 2022 to 2027.

Our exclusive multi-sensing modal technologies, combined with advanced AI and VR, have been extensively tested and proven to deliver exceptional clinical results. With a 95% accuracy rate in diagnosing Sensory Processing Disorder (SPD) and 93% accuracy in diagnosing ADHD, and an impressive 45% improvement rate in treating ADHD, our technologies stand apart in their performance. Among the 8 proof-of-concept candidates, four are now poised for regulatory approval in China and the United States.

Our founding team is comprised of seasoned investors, highly-skilled scientists, and healthcare professionals with interdisciplinary expertise. This unique blend of experience enables us to quickly identify potential business risks and develop sound strategies. Driven by a steadfast commitment to revolutionizing healthcare and empowering those struggling with behavioral difficulties, we are fully dedicated to ensuring the success of every strategic move we make.

Our distinctive industrial assets and business strategy position us to swiftly generate revenue – a key advantage that sets us apart from many seed-stage startups.